Lassa Virus Replicon Particle Vaccine Protects Strain 13/N Guinea Pigs Against Challenge With Geographically and Genetically Diverse Viral Strains.
Jessica R SpenglerMarkus H KainulainenStephen R WelchJoAnn D Coleman-McCrayJessica R HarmonJillian A CondreyFlorine E M ScholteStuart T NicholJoel M MontgomeryCésar G AlbariñoChristina F SpiropoulouPublished in: The Journal of infectious diseases (2022)
Lassa virus (LASV) causes mild to severe hemorrhagic fever disease in humans. Strain 13/N guinea pigs are highly susceptible to infection with LASV strain Josiah (clade IV), providing a critical model system for therapeutics and vaccine development. To develop additional models of disease, we detail the clinical course in guinea pigs infected with 5 geographically and genetically diverse LASV strains. Two of the developed models (LASV clades II and III) were then used to evaluate efficacy of a virus replicon particle vaccine against heterologous LASV challenge, demonstrating complete protection against clinical disease after a single vaccination dose.